Document Detail


Chromogranin A Is a Reliable Biomarker for Gastroenteropancreatic Neuroendocrine Tumors in an Asian Population of Patients.
MedLine Citation:
PMID:  22343505     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Purpose: To evaluate the significance of plasma chromogranin A (CgA) levels in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NET) in terms of disease status and treatment responses. Materials and Methods: Forty-four GEP-NET patients comprising 15 disease-free patients and 29 patients with active disease, as well as 26 healthy participants were enrolled in this study between April 2010 and April 2011. Clinicopathological factors were collected and serial plasma CgA levels were measured. Results: Plasma CgA levels were significantly higher in GEP-NET patients with active disease than in disease-free patients (p = 0.011) or healthy participants (p = 0.001). No difference in CgA levels was observed in terms of primary tumor location, tumor grade, and functional status in patients with active disease. CgA values at 94 U/l distinguished healthy individuals or disease-free patients from patients with active disease. Sensitivity and specificity rates were 86 and 88%, respectively. CgA levels at 110 U/l differentiated patients without recurrence from those with recurrence, with a sensitivity rate of 100% and a specificity rate of 80%. Patients (5/5, 100%) with stable disease and who showed partial response after treatment had a more than 20% decrease in CgA levels compared with the baseline values. Patients (6/6, 100%) with progressive disease showed a less than 20% decrease or increase in CgA levels. Conclusion: The plasma CgA level is a reliable biomarker for GEP-NET. We conclude that changes in CgA levels are associated with disease status and treatment responses.
Authors:
Wen-Chi Chou; Yu-Shin Hung; Jun-Te Hsu; Jen-Shi Chen; Chang-Hsien Lu; Tsann-Long Hwang; Kun-Ming Rau; Kun-Yun Yeh; Tse-Ching Chen; Chien-Feng Sun
Related Documents :
21349795 - Feature selection for accelerometer-based posture analysis in parkinsons disease.
3976705 - Clinical clues to the cause of addison's disease.
10234605 - 4,5-dimethyl-3-hydroxy-2[5h]-furanone (sotolone)--the odour of maple syrup urine disease.
9302395 - Inferior petrosal sinus avp in patients with cushing's syndrome.
19006475 - Calcineurin inhibitors for the treatment of atopic dermatitis.
20473135 - Could clinical profile influence csf biomarkers in early-onset alzheimer disease?
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-2-14
Journal Detail:
Title:  Neuroendocrinology     Volume:  -     ISSN:  1423-0194     ISO Abbreviation:  -     Publication Date:  2012 Feb 
Date Detail:
Created Date:  2012-2-20     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0035665     Medline TA:  Neuroendocrinology     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2012 S. Karger AG, Basel.
Affiliation:
Division of Hematology-Oncology and Departments Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine, Taoyuan, Taiwan, ROC.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  11C-Acetate PET/CT in localized prostate cancer: a study with MRI and histopathologic correlation.
Next Document:  Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agen...